Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker DNLI
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 3, 2026 | DNLI Denali Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 6, 2026 | DNLI Denali Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 28, 2026 | DNLI Denali Therapeutics Inc. | 2.01 Completion of Acquisition or Disposition of Assets | 8-K | 8-K ↗ |
| Jun 18, 2026 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jun 18, 2026 | DNLI Denali Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jun 4, 2026 | DNLI Denali Therapeutics Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 22, 2026 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| May 7, 2026 | DNLI Denali Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 3, 2026 | DNLI Denali Therapeutics Inc. | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Mar 31, 2026 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Mar 31, 2026 | DNLI Denali Therapeutics Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Mar 25, 2026 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Feb 26, 2026 | DNLI Denali Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 6, 2026 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Dec 10, 2025 | DNLI Denali Therapeutics Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Dec 10, 2025 | DNLI Denali Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Dec 4, 2025 | DNLI Denali Therapeutics Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Dec 4, 2025 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Dec 4, 2025 | DNLI Denali Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 6, 2025 | DNLI Denali Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 14, 2025 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 11, 2025 | DNLI Denali Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 7, 2025 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jun 3, 2025 | DNLI Denali Therapeutics Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jun 3, 2025 | DNLI Denali Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| May 6, 2025 | DNLI Denali Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 2, 2025 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Mar 5, 2025 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Feb 27, 2025 | DNLI Denali Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 27, 2025 | DNLI Denali Therapeutics Inc. | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Feb 27, 2025 | DNLI Denali Therapeutics Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jan 13, 2025 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 7, 2025 | DNLI Denali Therapeutics Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Nov 18, 2024 | DNLI Denali Therapeutics Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Nov 6, 2024 | DNLI Denali Therapeutics Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
35 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:11 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances